Hugo Albrecht is a senior lecturer at the University of South Australia conducting research and teaching activities within the Academic Unit of Clinical & Health Sciences. After obtaining his PhD at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland, he has gained considerable experience in both commercial and academic settings in Europe and the US. He has focused his research efforts in the fields of cancer, immunology and neuroscience. For over 20 years, Hugo has been dedicated to preclinical pharmaceutical development. He has led over 20 major drug discovery projects while working in industry and academia. Hugo’s current focus is on the development of biochemical and cell-based assay systems, and animal... Read more
About me
Hugo Albrecht is a senior lecturer at the University of South Australia conducting research and teaching activities within the Academic Unit of Clinical & Health Sciences. After obtaining his PhD at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland, he has gained considerable experience in both commercial and academic settings in Europe and the US. He has focused his research efforts in the fields of cancer, immunology and neuroscience. For over 20 years, Hugo has been dedicated to preclinical pharmaceutical development. He has led over 20 major drug discovery projects while working in industry and academia. Hugo’s current focus is on the development of biochemical and cell-based assay systems, and animal models to identify and test pharmacologically active compounds. Of current interest is the discovery of novel kinase inhibitors for cancer treatment. In line with this he is leading the design of functional nanoparticles for targeted delivery of drugs into tumour cells.
About me
Doctorate in Science University Lausanne Switzerland
Master in Science Federal School Zurich (ETHZ)
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2018 |
Open access
25
|
2018 |
Open access
35
26
5
|
2017 |
Open access
54
48
6
|
2016 |
24
20
4
|
2014 |
Open access
66
62
1
|
Year | Output |
---|---|
2023 |
Open access
|
2022 |
Open access
3
2
2
|
2022 |
Open access
3
3
7
|
2022 |
3
2
2
|
2021 |
Open access
46
34
2
|
2021 |
Open access
13
10
1
|
2021 |
Open access
3
5
|
2021 |
Open access
22
16
|
2020 |
8
10
1
|
2019 |
6
5
|
2019 |
Open access
9
7
3
|
2019 |
Open access
6
5
1
|
2019 |
Open access
23
18
1
|
2019 |
Open access
16
16
1
|
2018 |
Open access
25
|
2018 |
Open access
35
26
5
|
2017 |
Open access
22
18
|
2017 |
14
15
2
|
2017 |
Open access
32
29
|
2017 |
Open access
54
48
6
|
2016 |
19
18
|
2016 |
Open access
21
20
|
2016 |
Open access
50
46
5
|
2016 |
24
20
4
|
2015 |
Open access
15
15
|
2015 |
Open access
25
22
6
|
2015 |
27
25
4
|
2015 |
33
33
3
|
2014 |
Open access
66
62
1
|
2008 |
40
33
|
External engagement & recognition
Organisation | Country |
---|---|
Australian Synchrotron | AUSTRALIA |
CSIRO Australia (Commonwealth Scientific Industrial Research Organisation) | AUSTRALIA |
Shandong University | CHINA |
South Australian Health and Medical Research Institute (SAHMRI) | AUSTRALIA |
University of Adelaide | AUSTRALIA |
University of Applied Sciences and Arts Northwestern Switzerland | SWITZERLAND |
University of Applied Sciences Northwestern Switzerland | SWITZERLAND |
University of South Australia | AUSTRALIA |
Yabao Pharmaceutical Group Co., Ltd | CHINA |
Drug discovery, Drug development
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
111081 - Introducing a new paradigm for specific targeting of ovarian cancer cells with engineered nanoparticles, using G protein-coupled receptors as molecular entry points | Current |
111128 - Molecular mechanisms for growth plate cartilage degeneration after injury | Current |
An In-Vivo analysis of combination therapy of PPIs and H2 Blocker induced potential bone loss in Sprague Dawley rats model | Current |
Development of Cyclin Dependent Kinase Inhibitors for Cancer Treatment | Current |
Development of novel stimuli-responsive polysaccharides as delivery systems | Current |
Investigating the role of novel Tropomyosin receptor kinase (TRK) inhibitor for the treatment of NTRK fusion-positive lung cancer | Current |
Overcoming the hurdles of drug delivery for ovarian cancer: Preparation of targeted and pH-responsive nanoparticles loaded with Kinase and PARP Inhibitors. | Current |
Targeting ovarian cancer with nanoparticle drug carriers using G protein-coupled receptors as molecular entry sites | Current |
Design, synthesis, and evaluation of novel CDK2 inhibitors as potential anticancer agents | Completed |
Development of cyclin dependent kinase 9 inhibitors for the treatment of cancer | Completed |
Development of drug-eluting stents for the localised delivery of 5-fluorouracil targeted towards the treatment of gastrointestinal cancers | Completed |
Development of injectable hydrogels for the delivery of therapeutic agents | Completed |
Identification and characterisation of Mnk inhibitors as potential anti-cancer agents | Completed |
Novel cyclin-dependent kinase 9 inhibitors for the treatment of cancer: identification and preclinical evaluation | Completed |
Pre-clinical development of a CDK inhibitor for the treatment of cancer | Completed |
Pre-clinical Evaluation of FLT3 Inhibitors for Treatment of Acute Myeloid Leukaemia | Completed |
Preclinical evaluation of inhibitors of cyclin-dependent kinases 4 and 6 for the treatment of cancer | Completed |
Preclinical evaluation of novel dual CDK2/5 inhibitors as anticancer drug candidates | Completed |
Targeting prostate cancer cells with elastin like peptide based micelles displaying gastrin releasing peptide | Completed |